The Gut-Brain Connection: How Gluten Affects Your Focus

The gut-brain axis describes the complex network of neural, hormonal, and immunological pathways through which the gut and brain constantly communicate. At its core is the vagus nerve — the longest cranial nerve in the body — which carries signals bidirectionally between the enteric nervous system (the network of 500 million neurons embedded in the gut wall, sometimes called the "second brain") and the central nervous system in the brain. The gut also communicates with the brain through the production of neurotransmitters: approximately 90–95% of the body's serotonin is produced in the gut by enterochromaffin cells, and the gut also produces GABA, dopamine precursors, and a range of other neuroactive compounds. Gut bacteria contribute to this chemical signalling through the production of short-chain fatty acids, tryptophan metabolites, and other compounds that cross the intestinal barrier and, in some cases, the blood-brain barrier. The gut lining itself — a single cell layer thick, maintained by tight junction proteins — acts as a gatekeeper. When tight junction integrity is compromised (a state sometimes called intestinal permeability or "leaky gut"), incompletely digested food particles, bacterial products, and inflammatory molecules gain access to the bloodstream and potentially to the systemic and central nervous system. Understanding this architecture helps explain why gut pathology in coeliac disease produces consequences that extend far beyond the gut itself.

"Brain fog" — a colloquial but useful term for a cluster of cognitive difficulties including difficulty concentrating, slowed thinking, impaired short-term memory, and a sense of mental cloudiness — is reported by a substantial proportion of people with coeliac disease and non-coeliac gluten sensitivity. Several mechanisms have been proposed and partially evidenced. First, the systemic inflammation triggered by gluten in coeliac disease — mediated by elevated levels of pro-inflammatory cytokines including interleukin-6, interleukin-1-beta, and tumour necrosis factor alpha — crosses the blood-brain barrier and affects neuronal function, a well-documented phenomenon in other inflammatory conditions. Second, malabsorption of nutrients critical for brain function — including iron (which is essential for oxygen delivery and for the synthesis of neurotransmitters), vitamin B12 (required for myelin synthesis and nerve function), folate, zinc, and vitamin D — may directly impair cognitive performance. Third, research has identified a subset of coeliac patients who develop neurological manifestations including gluten ataxia (a cerebellar ataxia caused by antibody-mediated damage to the cerebellum) and peripheral neuropathy, suggesting that for some individuals the immune response has direct neurological targets. Fourth, disruption of the gut microbiome by the chronic inflammation of untreated coeliac disease may alter the production of neuroactive compounds from the gut, contributing to mood and cognitive changes through the gut-brain axis. In a systematic review of studies examining cognitive function in coeliac disease, cognitive impairments were consistently identified in adults with active coeliac disease, with partial improvement following adoption of a strict gluten-free diet.

The gut microbiome — the community of approximately 38 trillion bacteria, fungi, and other microorganisms that inhabit the large intestine — has emerged as a key mediator of the gut-brain connection and a potential contributor to mental health outcomes. Active coeliac disease is associated with significant dysbiosis: reduced microbial diversity, decreased levels of beneficial bacteria such as Lactobacillus and Bifidobacterium species, and elevated levels of potentially pathogenic bacteria. This microbiome disruption affects the production of short-chain fatty acids (including butyrate, which supports gut barrier integrity and has direct anti-inflammatory effects on the brain), tryptophan metabolism (which influences serotonin synthesis and therefore mood regulation), and GABA signalling. Several studies have identified higher rates of anxiety, depression, and quality-of-life impairments in adults with coeliac disease compared with the general population, and these differences are partially but not entirely explained by the burden of managing a chronic condition — one more reason that a structured gut-focused dietary protocol addressing both symptoms and psychological wellbeing matters. An intervention study published in Alimentary Pharmacology & Therapeutics found that adults with newly diagnosed coeliac disease showed significant improvements in anxiety and depression scores after 12 months on a strict gluten-free diet, with the improvements correlating with mucosal healing. Non-coeliac gluten sensitivity, while not associated with the same degree of microbiome disruption, is also associated with elevated rates of cognitive and mood symptoms that improve on a gluten-free diet in observational studies.

Zonulin — a protein discovered and characterised by gastroenterologist Dr Alessio Fasano — is the primary regulator of tight junction permeability between the cells of the intestinal lining. Gliadin, the key immunogenic component of gluten, is one of the most potent known triggers of zonulin release, and elevated serum zonulin levels are found in people with coeliac disease, non-coeliac gluten sensitivity, and several autoimmune conditions. When zonulin opens tight junctions, the gut becomes more permeable, allowing partially digested food antigens, bacterial lipopolysaccharides (LPS), and other immune-activating substances to enter the bloodstream — a state that drives systemic inflammation. LPS in the bloodstream activates the innate immune system and triggers a neuroinflammatory response in the brain that directly impairs synaptic plasticity, reduces the production of brain-derived neurotrophic factor (BDNF), and contributes to the cognitive symptoms characteristic of brain fog. The importance of this pathway extends beyond coeliac disease specifically — researchers are investigating the role of intestinal permeability in autism spectrum conditions, attention deficit disorders, depression, and neurodegenerative diseases, though causal relationships in these conditions remain to be definitively established. What is clear is that for individuals with established coeliac disease or gluten sensitivity, intestinal permeability is a real, measurable consequence of gluten exposure with demonstrable neurological implications.

The claim that eliminating gluten improves brain function in people without coeliac disease or diagnosed gluten sensitivity has become a cornerstone of popular dietary culture, yet the evidence is more nuanced than the marketing suggests. A double-blind, randomised controlled trial (the NCGS (Non-Coeliac Gluten Sensitivity) study in patients who had previously responded to a gluten-free diet) found that in a carefully controlled rechallenge protocol, gluten specifically (rather than other wheat components or FODMAPs) produced cognitive symptoms including brain fog in a subset of participants — suggesting that gluten-specific neurological effects do exist in some individuals without coeliac disease. However, several rigorous trials in healthy adults without any food intolerances have found no cognitive benefit from gluten elimination. A 2015 study published in the Journal of Nutrition found no difference in cognitive performance, mood, or gut symptoms between gluten and placebo conditions in healthy adults. The evidence therefore suggests that cognitive benefits from a gluten-free diet are real and clinically meaningful for those with coeliac disease and likely for a subset of people with non-coeliac gluten sensitivity — but are not supported by evidence for the general population.

For those who have identified gluten as a neurological trigger and are following a gluten-free diet, supporting the gut-brain axis more broadly can compound the cognitive and mood benefits of gluten elimination. Fermented foods — naturally gluten-free options include plain yogurt (if dairy is tolerated), kefir, kombucha, kimchi, sauerkraut, and miso — support microbiome diversity and may increase the production of neuroactive compounds including GABA and serotonin precursors, consistent with a Mediterranean dietary pattern that emphasises fermented foods and fibre-rich plant variety. High-fibre plant foods — which may be underrepresented on a diet that relies heavily on processed gluten-free products — provide the prebiotic substrate that beneficial gut bacteria require to produce short-chain fatty acids including butyrate. Omega-3 fatty acids (from oily fish, flaxseed, chia seeds, and walnuts) support neuronal membrane composition and have direct anti-inflammatory effects in the brain. Magnesium, which is involved in over 300 enzymatic reactions including many in the nervous system and is frequently deficient in people eating high amounts of refined gluten-free products, supports GABA function and has well-documented anxiolytic properties. Addressing any nutritional deficiencies resulting from malabsorption — particularly B12, iron, vitamin D, zinc, and folate — is arguably the most direct intervention for improving cognitive function in people with previously undiagnosed or poorly managed coeliac disease.